CUTTING EDGE
uro-oncology

MAT-NC-NON-2024-00021 05.02.2024

Information

Cutting Edge meeting, March 14-15 2024, Copenhagen

Cutting Edge is a Nordic meeting for senior and experienced oncologists and urologists. The Faculty* identifies the currently most discussed topics within the area of prostate cancer as well as bladder cancer and puts together an agenda with the purpose of bringing specialized speakers from around the world to the Nordics.

Agenda day 1

Thursday 14th March 2024

16.30 – 17.00	Arrival and coffee	
17.00 – 17.15	Welcome and introduction	
	PRIME TIME FOR INDIVIDUALISED TREATMENT IN mHSPC	*Chair:* Anders Bjartell
17.15 – 17.30	How to diagnose and treat oligometastatic disease?	Derya Tilki (DE)
17.30 – 17.45	Intensifying	Axel Heidenreich (DE)
17.45 – 18.00	De-escalation	Bertrand Tombal (BE)
18.00 – 18.15	Shared decision making	Sigrid Carlsson (US)
18.15 – 18.35	Discussion	
18.35 – 18.50	Break	
	NON-MUSCLE INVASIVE BLADDER CANCER	*Chair:* Jan Oldenburg
18.50 – 19.20	State of the Art	Marc-Oliver Grimm (DE)
19.20 – 19.25	Nordic perspective	Jan Oldenburg (NO)
19.25 – 19.40	Discussion	
20.00 – 22.00	Dinner – 10 year recap	Klaus Brasso (DK)

*The Faculty has representatives from three Nordic countries: Anders Bjartell (Sweden), Jan Oldenburg (Norway) and Klaus Brasso (Denmark).

astellas

Astellas Pharma a/s
Arne Jacobsens Allé 15, DK-2300 Copenhagen S
Telefon 4343 0355, kontakt.dk@astellas.com, www.astellas.dk

Astellas Pharma
kontakt.no@astellas.com
www.astellas.no

Astellas Pharma
info.fi@astellas.com
www.astellas.fi

Astellas Pharma AB
info.se@astellas.com
www.astellas.se

CUTTING EDGE
CUTTING EDGE
uro-oncology

Agenda day 2

Friday 15th March 2024

	PROSTATE CANCER PSA SCREENING: STATUS QUO AND QUO VADIS?	*Chair:* Anders Bjartell
08.30 – 08.45	Global perspective and recent trends	Sigrid Carlsson (US)
08.45 – 09.00	PSA Screening no	Philip Cornford (UK)
09.00 – 09.15	PSA Screening yes	Hendrik van Poppel (BE)
09.15 – 09.30	Discussion	
	SYSTEMIC MANAGEMENT OF UROTHELIAL CARCINOMA	*Chair:* Jan Oldenburg
09.30 – 09.45	Peri-operative treatments for localized UC	Maria De Santis (DE)
09.45 – 10.00	mUCC	Jan Oldenburg (NO)
10.00 – 10.15	Biomarkers	Karin Birkenkamp-Demtröder (DK)
10.15 – 10.30	Discussion	
10.30 – 10.50	Break	
	NEW OPPORTUNITIES AND CHALLENGES IN mCRPC	*Chair:* Anders Bjartell
10.50 – 11.05	Genetic testing	Elena Castro (ES)
11.05 – 11.20	PARP inhibitors	Bertrand Tombal (BE)
11.20 – 11.40	Companion diagnostics and recent results from ProBio	Henrik Grönberg (SE)
11.40 – 11.55	Role of PSMA PET	Philip Cornford (UK)
11.55 – 12.20	How to make sense of our clinical experience	Maria De Santis (DE) Philip Cornford (UK) Henrik Grönberg (SE)
12.20 – 12.35	Closing	Klaus Brasso
12.35 – 13.20	Lunch	

Denmark
Astellas respekterer samarbejdsaftalerne mellem Lif og de enkelte regioner. Invitationen til eventen vi blive sendt til den respektive sygehusledelse/afdelingsledelse, som træffer beslutning om deltagelse, herunder hvilke medarbejdere der deltager i aktiviteten.

Finland
Invitations will be sent to the Head of the respective clinic in line with the applicable rules in this area.

Norway
Invitasjon vil bli sendt i henhold til gjeldende regelverk ved de respektive helseforetak. From the LMI Code section 15.2: For digital information about company meetings/seminars communicated to Health Trust employees, the following applies: 1. Member companies can inform about meetings/seminars in electronic newsletters, e-mails, social media or advertisements on websites etc. The information may provide info about the topic of the meeting, meeting format (physical / digital), date and possibly place of the meeting (for example hotel or city). One may, for example, write "read more here" and then be directed to more info about the meeting. The e-mail / newsletter cannot appear as an invitation; therefore one should not have a registration link in the information.

Sweden
Invitation has been sent to doctors working with oncology treatment, with copy to operations manager. According to the agreement between LIF and SKR, pharmaceutical companies may not cover the cost of either travel or accommodation. For this reason, each participant is responsible for booking and paying its own travel and accommodation. Remember that the participant is responsible for the employer's approval to participate in the meeting.

astellas

Astellas Pharma a/s
Arne Jacobsens Allé 15, DK-2300 Copenhagen S
Telefon 4343 0355, kontakt.dk@astellas.com, www.astellas.dk

Astellas Pharma
kontakt.no@astellas.com
www.astellas.no

Astellas Pharma
info.fi@astellas.com
www.astellas.fi

Astellas Pharma AB
info.se@astellas.com
www.astellas.se